Duncan Jason reported grant involving 375,000 derivative units of Neumora Therapeutics, Inc. at $0.00 for $0 on Aug 20, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
See Remarks
See Remarks
Filed Aug 21, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
375,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
375,000Direct
Trade date
Aug 20, 2026Grant
Filed
Aug 21, 2026, 7:08 PM ET1-day reporting delay
Accession
0001610717-26-000383Code A · Transaction 31079
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

NMRA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
NMRA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −1.2%1w ago +6.1%1d ago +0.6%
Returns since7d −15%30d −55%90d180d1y

Footnotes in full

F1: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.